A Phase 2 interventional study of ELX-02 in Genetic Disease, Nonsense Mutation and Cystinosis, sponsored by Eloxx Pharmaceuticals, Inc.. Terminated at 1 site in Canada. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-05-27.
Sponsored by Eloxx Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 in patients with cystinosis with nonsense mutation in at least one allele.
Six patients will be enrolled in the trial.
The study will comprise of the following periods for each patient:
Each patient will receive three escalating doses as follows:
47 studies on the registry are indexed under Cystinosis; 15 are open to participants now.
This study's enrollment of 3 is below the median of 30 across 27 interventional studies indexed under Cystinosis.
Browse Cystinosis studies →Eloxx Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Compared within Cystinosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients must meet all of the following criteria to participate in this study:
Patients with any of the following characteristics/conditions will not be included in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eukaryotic ribosomal selective glycoside (ERSG)
Drug: ELX-02
ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
AEs associated with different dose levels of ELX-02
Time frame: From the time of first dosing through the follow-up visit, an average of approximately 10 weeks
Area under the plasma concentration curve from time zero to 24 hours (AUC0-24h)
Full PK profile 12 blood samples over 24 hours
Time frame: Day 1 of treatment periods 1, 2, and 3
Maximum observed plasma concentration (Cmax)
Full PK profile 12 blood samples over 24 hours
Time frame: Day 1 of treatment periods 1, 2, and 3
Observed plasma concentration at 1 hour post dose (C1h)
Sparse sampling, blood sampling only, pre-dose and 1 hour post dose
Time frame: Days 1, 2, 5, and 7 of treatment periods 1-2; Days 1, 2, 5, 7, 10, and 14 of treatment period 3
Amount of ELX-02 excreted in urine from 0 to 24 hours (Ae24h)
6 urine collections over 24 hours
Time frame: Day 1 of treatment periods 1, 2, and 3
Renal clearance on Day 1 (Ae24h/plasma AUC0-24h)
6 urine collections over 24 hours
Time frame: Day 1 of treatment periods 1, 2, and 3
Changes from baseline in WBC cystine levels
Time frame: Screening; Days 1, 2, 5, and 7 of treatment periods 1-2; Days 1, 2, 5, 7, 10, and 14 of treatment period 3, and 4-week safety follow-up
Ran from Aug 2019 to primary completion in Dec 2019, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ELX-02
Eloxx Pharmaceuticals, Inc.